|
SEREX-defined breast cancer antigens: Antigens
reactive with sera
from breast cancer patients and patients with other forms of cancer1.
|
NY-BR-Antigen
|
Identity/Similarities/Motifs
(Unigene
cluster)
|
SEREX
Database ID Number2 of Equivalent Isolate
(Tumor
Source3)
|
Seroreactivity
|
|
Breast
Cancer
|
Colon
Cancer
|
Lung
Cancer
|
Ovarian
Cancer
|
Esophageal
Cancer
|
|
25
|
KIAA0854
protein, (Hs.30209)
|
128
(RC)
|
1/25
|
1/19
|
0/15
|
1/15
|
0/15
|
|
34
|
SHB
adaptor protein (Hs.173752)
|
|
1/25
|
0/19
|
0/15
|
1/15
|
0/15
|
|
41
|
SNT-1
adaptor (Hs.251394)
|
|
1/25
|
0/19
|
1/15
|
0/15
|
0/15
|
|
45
|
Kinesin
2 (Hs.117977)
|
332
(GC), 96 (SM), 797 (RC)
|
2/25
|
0/19
|
0/15
|
0/15
|
0/15
|
|
53
|
LAGE-14
(Hs.167379)
|
|
4/25
|
1/19
|
2/15
|
1/15
|
2/15
|
|
55
|
Nucleosome
assembly protein-1 (Hs.179662)
|
126
(RC), 1137 (MEL)
|
1/25
|
1/19
|
1/15
|
0/15
|
0/15
|
|
56
|
gC1Q
binding protein (Hs.78614)
|
|
2/25
|
0/19
|
0/15
|
0/15
|
0/15
|
|
57
|
HER2
neu/erbB2 (Hs.173664)
|
|
2/25
|
0/19
|
0/15
|
0/15
|
0/15
|
|
62
|
Novel,
kinesin similarity (Hs.278323)
|
|
2/25
|
0/19
|
0/15
|
0/15
|
0/15
|
|
63
|
Tumor
protein D52 (Hs.2384)
|
|
2/25
|
0/19
|
0/15
|
0/15
|
0/15
|
|
72
|
MAGE
A6 (Hs.198263)
|
|
1/25
|
0/19
|
0/15
|
1/15
|
0/15
|
|
75
|
Novel
(Hs.5111)
|
1184
(MEL)
|
2/25
|
0/19
|
0/15
|
0/15
|
1/15
|
|
79
|
Tata
element modulatory factor 1 (Hs.74985)
|
246
(GC)
|
1/25
|
0/19
|
0/15
|
0/15
|
0/15
|
|
94
|
Tumor
protein p53 (Hs.1846)
|
33
(CC)
|
1/25
|
3/19
|
0/15
|
1/15
|
2/15
|
|
96
|
Novel,
S/T kinase domain (Hs.4789)
|
296
(MEL)
|
2/25
|
0/19
|
0/15
|
0/15
|
0/15
|
|
98
|
MAGE
D (Hs.4943)
|
|
3/25
|
0/19
|
1/15
|
0/15
|
0/15
|
1Antigens did not react with sera from normal individuals
(0/25).
2SEREX database ID number from http://www.licr.org/SEREX.html.
3Abbreviations: BC, breast cancer; CC, colon cancer;
GC, gastric cancer; MEL, melanoma; RC, renal cancer; SM, seminoma.
4Assays for LAGE-1 seroreactivity were performed using
a recombinant phage expressing the highly homologous NY-ESO-1
protein.
|
